Integrity Advisory’s Novo Nordisk NVO Stock Holding History

Integrity Advisory’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$224K	Buy	+3,312	New	+$194K	0.21%	69

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Integrity Advisory's NVO Position: Q4 2022 in Review

Integrity Advisory opened a new position in Novo Nordisk (NVO) in Q4 2022: 3,312 shares worth $224K. The stake represents 0.21% of the portfolio and ranks #69 among its holdings.

1,049 funds tracked by Wall St. Rank hold NVO as of Q4 2022.

Integrity Advisory held 3,312 shares of Novo Nordisk worth $224K as of Q4 2022.
Novo Nordisk was a new Integrity Advisory position in Q4 2022.
Novo Nordisk made up 0.21% of Integrity Advisory's portfolio in Q4 2022, its #69 holding.
1,049 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2022.

Based on Integrity Advisory's 13F filing for Q4 2022, filed 24 Jan 2023.